These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant. Parekh A; Srivastava S; Bena J; Albini T; Nguyen QD; Goldstein DA JAMA Ophthalmol; 2015 May; 133(5):568-73. PubMed ID: 25719937 [TBL] [Abstract][Full Text] [Related]
65. Posterior sub-Tenon's triamcinolone injections in the treatment of uveitis. Tanner V; Kanski JJ; Frith PA Eye (Lond); 1998; 12 ( Pt 4)():679-85. PubMed ID: 9850264 [TBL] [Abstract][Full Text] [Related]
66. Orbital floor triamcinolone acetonide injections for the management of active non-infectious uveitis. Roesel M; Gutfleisch M; Heinz C; Heimes B; Zurek-Imhoff B; Heiligenhaus A Eye (Lond); 2009 Apr; 23(4):910-4. PubMed ID: 18464803 [TBL] [Abstract][Full Text] [Related]
67. New developments in corticosteroid therapy for uveitis. Taylor SR; Isa H; Joshi L; Lightman S Ophthalmologica; 2010; 224 Suppl 1():46-53. PubMed ID: 20714181 [TBL] [Abstract][Full Text] [Related]
69. Efficacy and safety of intravitreal and periocular injection of corticosteroids in noninfectious uveitis: a systematic review. José-Vieira R; Ferreira A; Menéres P; Sousa-Pinto B; Figueira L Surv Ophthalmol; 2022; 67(4):991-1013. PubMed ID: 34896190 [TBL] [Abstract][Full Text] [Related]
70. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model. Chen M; Li X; Liu J; Han Y; Cheng L J Control Release; 2015 Apr; 203():109-17. PubMed ID: 25700623 [TBL] [Abstract][Full Text] [Related]
71. Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation. Levin DS; Han DP; Dev S; Wirostko WJ; Mieler WF; Connor TB; George V; Eastwood D Am J Ophthalmol; 2002 Feb; 133(2):196-202. PubMed ID: 11812422 [TBL] [Abstract][Full Text] [Related]
75. Intraocular Pressure Elevation After Posterior Subtenon Triamcinolone Acetonide Injection in Pediatric Non-Infectious Uveitis. Yalcinsoy KO; Ozdal PC; Sen E; Elgin U Beyoglu Eye J; 2022; 7(4):298-303. PubMed ID: 36628084 [TBL] [Abstract][Full Text] [Related]
76. Re: Outcome of raised intraocular pressure in uveitic eyes with and without a corticosteroid-induced hypertensive response. Nazm N; Dubey S; Gandhi M; Pegu J Am J Ophthalmol; 2010 Mar; 149(3):525-6; author reply 526-7. PubMed ID: 20172078 [No Abstract] [Full Text] [Related]
77. [Effects of analysis of posterior subtenon injection of triamcinolone: a case series]. Zajdenweber ME; Moraes RT; Muccioli C Arq Bras Oftalmol; 2006; 69(4):509-11. PubMed ID: 17119722 [TBL] [Abstract][Full Text] [Related]
78. Glycosylation-enhanced biocompatibility of the supramolecular hydrogel of an anti-inflammatory drug for topical suppression of inflammation. Xiong T; Li X; Zhou Y; Song Q; Zhang R; Lei L; Li X Acta Biomater; 2018 Jun; 73():275-284. PubMed ID: 29660509 [TBL] [Abstract][Full Text] [Related]
79. Orbital floor steroid injections in the treatment of uveitis. Riordan-Eva P; Lightman S Eye (Lond); 1994; 8 ( Pt 1)():66-9. PubMed ID: 8013721 [TBL] [Abstract][Full Text] [Related]
80. Three methods of treatment of chalazia in children. Mustafa TA; Oriafage IH Saudi Med J; 2001 Nov; 22(11):968-72. PubMed ID: 11744967 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]